Curcumin: An age-old anti-inflammatory and anti-neoplastic agent

Journal of Traditional and Complementary Medicine

Volumn 7, Issue 3, 2017, Pages 339-346

  Fadus, Matthew C ^a   Lau, Cecilia ^b   Bikhchandani, Jai ^c   Lynch, Henry T ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b DUKE UNIVERSITY   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory; Cancer; Chemoprophylaxis; Curcumin; Curry; Turmeric

Indexed keywords

EID: 84995467728     PISSN: None     EISSN: 22254110     Source Type: Journal    
DOI: 10.1016/j.jtcme.2016.08.002     Document Type: Review

References (64)

1. Goel, A., Kunnumakkara, A.B., Aggarwal, B.B., Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol, 2007, 10.1016/j.bcp.2007.08.016.
2. Aggarwal, B.B., Takada, Y., Oommen, O.V., From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 13 (2004), 1327–1338.
3. Eigner, D., Scholz, D., Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 67 (1999), 1–6.
4. Basnet, Purusotam, Skalko-Basnet, Natasa, Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 2011, 4567–4598.
5. Wang, Ke, Fan, Hua, Chen, Qingsen, et al. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro. Anti-Cancer Drugs 26:1 (2015), 15–24.
6. Aggarwal, B.B., Surh, Y.J., Shishodia, S., The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol, 2007, 595 Springer publication.
7. Gupta, Subash C., Patchva, Sridevi, Aggarwal, Bharat B., Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15:1 (2012), 195–218.
8. Skrzypczak-Jankun, E., Zhou, K., McCabe, N.P., Selman, S.H., Jankun, J., Structure of curcumin in complex with lipoxygenase and its significance in cancer. Int J Mol Med 12 (2003), 17–24.
9. Shim, J.S., Kim, J.H., Cho, H.Y., et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol 10 (2003), 695–704.
10. Yang, F., Lim, G.P., Begum, A.N., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280 (2005), 5892–5901.
11. Gaedeke, J., Noble, N.A., Border, W.A., Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int 68 (2005), 2042–2049 [86] McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ.
12. Mcnally, Stephen, Harrison, Ewen, Ross, James, Garden, O., Wigmore, Stephen, Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, P38 activation and phosphatase inhibition. Int J Mol Med, 19(1), 2007.
13. Shishodia, S., Singh, T., Chaturvedi, M.M., Modulation of transcription factors by curcumin. Adv Exp Med Biol 595 (2007), 127–148.
14. Lengyel, E., Sawada, K., Salgia, R., Tyrosine kinase mutations in human cancer. Curr Mol Med 7 (2007), 77–84.
15. Tikhomirov, O., Carpenter, G., Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 63 (2003), 39–43.
16. Aoki, H., Takada, Y., Kondo, S., Sawaya, R., Aggarwal, B.B., Kondo, Y., Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and ERK signaling pathways. Mol Pharmacol 72:1 (2007), 29–39.
17. Li, M., Zhang, Z., Hill, D.L., Wang, H., Zhang, R., Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67 (2007), 1988–1996.
18. Song, G., Mao, Y.B., Cai, Q.F., Yao, L.M., Ouyang, G.L., Bao, S.D., Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosisrelated protein expression. Braz J Med Biol Res 38 (2005), 1791–1798.
19. Liontas, A., Yeger, H., Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 24 (2004), 987–998.
20. Huang, M., Lysz, T., Ferraro, T., Abidi, T., Laskin, J., Conney, A., Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activity. Cacner Res 51 (1991), 813–819.
21. Pan, M.H., Huang, T.M., Lin, J.K., Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27 (1999), 486–494.
22. Ireson, C., Orr, S., Jones, D.J., et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbolester-induced prostaglandin E2 production. Cancer Res 61 (2001), 1058–1064.
23. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P.S., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64 (1998), 353–356.
24. Cheng, A.L., Hsu, C.H., Lin, J.K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (2001), 2895–2900.
25. Sharma, R.A., Euden, S.A., Platton, S.L., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10 (2004 Oct 15), 6847–6854.
26. Kanai, M., Imaizumi, A., Otsuka, Y., et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 69 (2012), 65–70.
27. Chandran, B., Goel, A., A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res Phytother Res 26:11 (2012), 1719–1725.
28. Gerrits, J., Wetering, J., Weimar, W., Besouw, N., T-Cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients. Transplantation 8:2 (2010), 907–914.
29. Kang, Q., Chen, A., Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol 157:8 (2009), 1354–1367.
30. Caesar, I., Jonson, M., Nilsson, K., Thor, S., Hammarström, P., Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS One, 7(2), 2012 Retrieved September 25, 2015, from http://dx.doi.org/10.1371/journal.pone.0031424.
31. Mathew, A., Fukuda, T., Nagaoka, Y., et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One, 7(3), 2012.
32. Midura-Kiela, M., Radhakrishnan, V., Larmonier, C., Laubitz, D., Ghishan, F., Kiela, P., Curcumin inhibits interferon- signaling in colonic epithelial cells. AJP Gastrointest Liver Physiol 302:1 (2011), G85–G96.
33. Ravindranath, V., Chandrasekhara, N., Metabolism of curcumin—studies with [3H]curcumin. Toxicology 22:no. 4 (1982), 337–344.
34. Kumar, S., Ahuja, V., Vishnubhatla, S., Prasad, K., Kumar, A., Curcumin for maintenance of remission in ulcerative colitis. Protoc Cochrane Database Syst Rev, 10, 1996.
35. Epelbaum, R., Schaffer, M., Vizel, B., Badmaev, V., Bar-Sela, G., Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62 (2010 Nov), 1137–1141.
36. Bayet-Robert, M., Morvan, D., Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLoS One, 8(3), 2013.
37. Zhou, D., Ding, N., Du, Z., et al. Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation. Mol Med Rep Mol Med Rep 10:3 (2014), 1315–1322.
38. Gupta, S., Patchva, S., Aggarwal, B., Therapeutic roles of curcumin: lessons learned from clinical trials. APPS J, 15(No 1), January 2013.
39. Polasa, K., Raghuram, T.C., Krishna, T.P., Krishnaswamy, K., Effect of turmeric on urinary mutagens in smokers. Mutagenesis 7:2 (1992), 107–109, 10.1093/mutage/7.2.107.
40. Jemal, A., Siegel, R., Ward, E., et al. Cancer statistics, 2008. CA Cancer J Clin 58:2 (2008), 71–96.
41. Todaro, M., Francipane, M.G., Medema, J.P., Stassi, G., Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138 (2010), 2151–2162.
42. Abdul Khalek, F.J., Gallicano, G.I., Mishra, L., Colon cancer stem cells. Gastrointest Cancer Res, 2010, S16–S23.
43. Yu, Y., Kanwar, S.S., Patel, B.B., Nautiyal, J., Sarkar, F.H., Majumdar, A.P., Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2:4 (2009), 321–328.
44. Dick, J.E., Stem cell concepts renew cancer research. Blood 112:13 (2008), 4793–4807.
45. Wang, J.C., Dick, J.E., Cancer stem cells: lessons from leukemia. Trends Cell Biol 15:9 (2005), 494–501.
46. Boman, B.M., Huang, E., Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26 (2008), 2828–2838.
47. Schiavoni, G., Gabriele, L., Mattei, F., The tumor microenvironment: a pitch for multiple players. Front Oncol, 3, 2013.
48. Buhrmann, C., Kraehe, P., Lueders, C., Shayan, P., Goel, A., Shakibaei, M., Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT. Sethi, G., (eds.) PLoS One, 9(9), 2014, e107514, 10.1371/journal.pone.0107514.
49. Gout, S., Huot, J., Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 1 (2008), 69–83.
50. Boral, D., Nie, D., Cancer stem cells and niche mircoenvironments. Front Biosci (Elite Ed) 4 (2012), 2502–2514.
51. Pin, A.L., Houle, F., Huot, J., Recent advances in colorectal cancer research: the microenvironment impact. Cancer Microenviron 4 (2011), 127–131, 10.1007/s12307-011-000-y.
52. Irving, G.R., Karmokar, A., Berry, D.P., Brown, K., Steward, W.P., Curcumin: the potential for efficacy in gastrointestinal diseases. Best Pract Res Clin Gastroenterol 25 (2011), 519–534.
53. Irving, G.R., Howells, L.M., Sale, S., et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration—a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila) 6 (2013), 119–128.
54. Li, L., Ahmed, B., Mehta, K., Kurzrock, R., Liposomal curcumin 1570 with and without oxaliplatin: effects on cell growth, 1571 apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6 (2007), 1276–1282.
55. Garcea, G., Jones, D.J., Singh, R., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90 (2004 Mar 8), 1011–1015.
56. Carroll, R.E., Benya, R.V., Turgeon, D.K., et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 4 (2011), 354–364.
57. Ireson, C.R., Jones, D.J., Orr, S., et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11 (2002), 105–111.
58. Naz, R.K., Lough, M.L., Curcumin as a potential non-steroidal contraceptive with spermicidal and microbicidal properties. Eur J Obstet Gynecol Reprod Biol 176 (2014), 142–148.
59. Jiao, Y., Wilkinson, J., Di, X., et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113 (2009), 462–469.
60. Hata, M., Sasaki, E., Ota, M., Fujimoto, K., Yajima, J., Shichida, T., et al. Allergic contact dermatitis from curcumin 1827 (turmeric). Contact Dermat 36 (1997), 107–108.
61. Burgos-Moron, E., Calderon-Montano, J.M., Salvador, J., Robles, A., Lopez-Lazaro, M., The dark side of curcumin. Int J Cancer 126:7 (2010), 1771–1775.
62. Kanai, M., Otsuka, Y., Otsuka, K., et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 71 (2013), 1521–1530.
63. Lopez-Lazaro, M., Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52:suppl 1 (2008), S103–S127.
64. Syng-Ai, C., Kumari, A.L., Khar, A., Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 3 (2004), 1101–1108.